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respectively. Diarrhea (6.3%), fatigue (3.2%) and dyspnea (3.2%) were 
the most common grade 3/4 non-hematological toxicities. The most 
common drug-related toxicities (any grade) were pyrexia (11.6%), 
vomiting, nausea, diarrhea and asthenia (9.5%) and fatigue (8.4%). Tu-
mor Response Rate (CR/PR) in treated patients was 9.2%. The survival 
at 4.5 months (median follow-up) was 79% and the median PFS was 
3.1 months. Twenty patients (21.1%) died mainly because of disease 
progression.
Conclusion: Patients with locally advanced or metastatic NSCLC 
could beneﬁt from second-line pemetrexed, with a low incidence of 
hematological and non-hematological toxicities.
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The Ataxia Telangiectasia Mutated (ATM) gene is known to be a pro-
tein kinase that plays a central mediator of responses to DNA double-
strand breaks in cells. Therefore, ATM gene polymorphisms may act as 
important factors predicting the outcome of non-small cell lung cancer 
(NSCLC) patients treated with platinum combination. In order to evalu-
ate the role of ATM gene polymorphisms, seven genotypes of the ATM 
polymorphisms, IVS16-56G>A, IVS17+910G>A, IVS19-657G>A, 
IVS21-76C>T, IVS34-822C>T, IVS62+60A>G, IVS62-973A>C 
were determined in 300 Korean NSCLC patients who were staged as 
IIIA(n=48), IIIB (n=93) and IV (n=159). One-, three-, ﬁve-year sur-
vival was shown to be 57.6%, 11.7%, 4.7% respectively. Clinical stage, 
performance status, body weight loss (>5%) or response status to the 
treatment was correlated signiﬁcantly with survival (P=0.027, 0.038, 
0.076 <0.001 respectively). The frequencies for major and minor allele 
were as followings: 56% and 44% for IVS16-56G>A, 88% and 12% 
for IVS17+910G>A, 68% and 32% for IVS19-657G>A, 61% and 39% 
for IVS21-76C>T, 64% and 36% for IVS34-822C>T, 52% and 48% for 
IVS62+60A>G, 60% and 40% for IVS62-973A>C. When the effects of 
selected ATM genotypes were evaluated, any ATM genotype was not 
shown to have association with survival (log rank P=0.317 for IVS16-
56G>A, 0.451 for IVS17+910G>A, 0.520 for IVS19-657G>A, 0.542 
for IVS21-76C>T, 0.272 for IVS34-822C>T, 0.371 for IVS62+60A>G, 
0.470 for IVS62-973A>C). Therefore, our results suggest that poly-
morphisms of the ATM gene can not confer prognostic relevance in 
NSCLC patients treated with platinum combination. 
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Background: Because elderly pts may tolerate platinum-based combi-
nation chemotherapy poorly, single-agent chemotherapy is selected for 
the treatment regimen. However, retrospective subgroup analyses have 
consistently indicated that elderly pts indeed beneﬁt from platinum-
based combination chemotherapy as well as their younger counterparts. 
This phase II study evaluated the efﬁcacy and safety of carboplatin/
gemcitabine combination chemotherapy in elderly pts with advanced 
NSCLC.
Methods: Fifty-four pts aged more than 70 years old (median, 77; 
range, 70-88) with previously untreated advanced NSCLC were 
enrolled on this trial. Additional criteria included the presence of mea-
surable lesions, an Eastern Cooperative Oncology Group performance 
status of 0 or 1, and adequate organ function. Pts received carboplatin 
at an area under the curve of 4 mg/ml/min on the ﬁrst day and gem-
citabine at 1000 mg/m2 on the ﬁrst and eighth day of consecutive 3 
week periods. The primary endpoint was to determine the objective 
response rate of this platinum-doublet regimen. The RECIST criteria 
were used to measure response. 
Results: Enrolled pts included 15/39 with stage IIIB/IV diseases. Fifty-
one out of enrolled pts were eligible for efﬁcacy and safety analyses. 
The median number of treatment cycles was 4 (range, 1-7). Fifteen 
partial responses (response rate: 29%) were obtained. The median TTP 
was 3.9 months, and median overall survival was 15.9 months. Hema-
tological toxicities of grade 3/4 included leukopenia (46%), neutrope-
nia (72%) and thrombocytopenia (50%). Non-hematological toxicities 
of grade 3/4 included nausea (6%), appetite loss (7%), fatigue (7%) and 
infection (9%). 
Conclusion: The combination carboplatin-gemcitabine at these doses 
has shown activity with a favorable toxicity proﬁle for ﬁt elderly pts 
with advanced NSCLC.
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Background: Gemcitabine plus carboplatin (GC) therapy is active as 
ﬁrst-line treatment in advanced non-small-cell lung cancer (NSCLC). 
For nonprogressing patients, the timing of second-line chemotherapy 
for optimum clinical beneﬁt is uncertain. Docetaxel (D) is approved for 
second-line therapy in advanced NSCLC. This Phase III, randomized 
trial assessed the efﬁcacy and safety of D administered either immedi-
ately after initial GC therapy or upon disease progression (PD). 
Methods: Patients enrolled had either Stage IIIB with pleural effusion 
or Stage IV NSCLC. Prior chemotherapy for NSCLC was excluded. 
Gemcitabine 1000 mg/m2 was administered on Days 1, 8 followed by 
carboplatin AUC 5 on Day 1. After four 21-day cycles, nonprogres-
sors were randomized to either immediate D group (D 75 mg/m2 on 
Day 1 every 21 days, maximum of 6 cycles) or delayed D group (best 
